Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00662506 · ClinicalTrials.gov registry record · Phase 1
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00662506: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00662506 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00662506, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This phase I/II trial is studying the side effects and best dose of cediranib to see how well it works when given together with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cediranib together with temozolomide and radiation therapy may kill more tumor cells.
Interventions
- RADIATION Fludeoxyglucose F-18
- PROCEDURE Diffusion Weighted Imaging
- PROCEDURE Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- DRUG Cediranib Maleate
- PROCEDURE Diffusion Tensor Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2008-04 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00662506
The ClinicalTrials.gov registry entry for NCT00662506 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludeoxyglucose F-18 is the first listed.
NCT00662506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00662506 about?
NCT00662506 is a clinical study titled "Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma". This phase I/II trial is studying the side effects and best dose of cediranib to see how well it works when given together with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma. Cediranib may stop the growth of tumor cells by blocking some of the enzymes need...
What is the current status of trial NCT00662506?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2008-04. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00662506?
The interventions under investigation include: Fludeoxyglucose F-18 (RADIATION), Diffusion Weighted Imaging (PROCEDURE), Dynamic Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), Cediranib Maleate (DRUG), Diffusion Tensor Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT00662506?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.